2 January 2023 - Advantages in overall survival and in relapses often only become apparent after a long period of ...
16 December 2022 - A team led by IQWiG authors compared the usual beta-binomial model for meta-analysis of small study pools ...
9 December 2022 - A team led by IQWiG authors systematically compares instruments for measuring the treatment effects of disease-modifying ...
6 December 2022 - Revision of the cost-benefit assessment and addition of the concept of application-accompanying data collection: Comments on ...
5 December 2022 - The final report of the IQWiG on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab ...
5 December 2022 - National health technology assessments across Europe show differences in evidentiary requirements from assessments by the EMA, affecting ...
5 December 2022 - A redesign of consumer cost sharing in the US is important to accelerate the adoption of biosimilars ...
1 December 2022 - Adjuvant treatment with olaparib can prolong life and prevent recurrence in early breast cancer. However, it ...
2 November 2022 - There is a hint of a major added benefit compared to chemotherapy with cisplatin or carboplatin, each ...
25 October 2022 - Digitisation has potential when it comes to making clinical development for the care of rare diseases more ...
26 October 2022 - The German regulation of pricing and reimbursement of pharmaceuticals is probably one of the most complicated legal ...
4 October 2022 - However, due to contra-indications and interactions, the combination of active ingredients is not suitable for all patients ...
5 October 2022 - For post-menopausal women with hormone receptor positive, HER2 negative breast cancer in the first line, there is ...
15 September 2022 - IQWiG authors present the advantages and disadvantages of study designs that combine explanatory and pragmatic aspects. ...
8 September 2022 - To assess the clinical relevance of patient reported outcomes, a response threshold of ≥ 15% of the ...